Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Hyperhidrosis: An Update

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Hyperhidrosis is a dermatosis presenting as pathologically excessive focal or generalized sweating. The stigmatizing nature of hyperhidrosis may cause patients to feel embarrassment and apprehension about their symptoms and experience a significant decrease in well-being. Severe cases of hyperhidrosis can also increase the risk of developing psychiatric and somatic comorbidities. Conventional non-surgical treatments of hyperhidrosis include aluminum salts, iontophoresis, botulinum toxin injections, and oral glycopyrronium. In recent years, new topical anticholinergic medications and devices have emerged that may improve the patients’ symptoms and even prevent the development of comorbidities. The treatment of hyperhidrosis can be a complex matter and may require the combination of several therapies. The purpose of this paper was to firstly review the literature on existing non-surgical treatment options for hyperhidrosis, and secondly provide a stepwise approach to investigating and treating patients with hyperhidrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–86.

    Article  PubMed  Google Scholar 

  2. Li X, Chen R, Tu YR, Lin M, Lai FC, Li YP, et al. Epidemiological survey of primary palmar hyperhidrosis in adolescents. Chin Med J (Engl). 2007;120(24):2215–7.

    Article  Google Scholar 

  3. Tu YR, Li X, Lin M, Lai FC, Li YP, Chen JF, et al. Epidemiological survey of primary palmar hyperhidrosis in adolescent in Fuzhou of People’s Republic of China. Eur J Cardiothorac Surg. 2007;31(4):737–9.

    Article  PubMed  Google Scholar 

  4. Gross KM, Schote AB, Schneider KK, Schulz A, Meyer J. Elevated social stress levels and depressive symptoms in primary hyperhidrosis. PLoS One. 2014;9(3): e92412.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Henning MAS, Ibler KS, Loft I, Ostrowski SR, Erikstrup C, Nielsen KR, et al. The health-related quality of life in hyperhidrosis and co-morbidities. Qual Life Res; 2022.

  6. Deckers IE, Kimball AB. The handicap of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):17–22.

    Article  CAS  PubMed  Google Scholar 

  7. Kristensen JK, Grejsen D, Swartling C, Bygum A. In hyperhidrosis quality of life is even worse than in acne, eczema, or psoriasis. A comparison of Skindex-16 and Dermatology Life Quality Index (DLQI). Int J Dermatol. 2020.

  8. Shayesteh A, Janlert U, Nylander E. Hyperhidrosis—sweating sites matter: quality of life in primary hyperhidrosis according to the sweating sites measured by SF-36. Dermatology. 2017;233(6):441–5.

    Article  PubMed  Google Scholar 

  9. Henning MAS, Ibler KS, Ostrowski SR, Erikstrup C, Nielsen KR, Bruun MT, et al. Hyperhidrosis and the risk of being treated for skin infections. J Dermatol Treat. 2021:1–7.

  10. Lessa Lda R, Luz FB, De Rezende RM, Duraes SM, Harrison BJ, De Menezes GB, et al. The psychiatric facet of hyperhidrosis: demographics, disability, quality of life, and associated psychopathology. J Psychiatr Pract. 2014;20(4):316–23.

    Article  PubMed  Google Scholar 

  11. Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol. 2016;75(6):1126–33.

    Article  PubMed  Google Scholar 

  12. Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case–control study of 387 patients. J Am Acad Dermatol. 2009;61(2):242–6.

    Article  PubMed  Google Scholar 

  13. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Obed D, Salim M, Bingoel AS, Hofmann TR, Vogt PM, Krezdorn N. Botulinum toxin versus placebo: a meta-analysis of treatment and quality-of-life outcomes for hyperhidrosis. Aesthetic Plast Surg. 2021;45(4):1783–91.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Parrish C, Waldbaum B, Coleman D, Blevins C, Rodgers K, Lee B, et al. Microwave thermolysis reduces generalized and social anxiety in young adults with axillary hyperhidrosis. Lasers Surg Med. 2020;52(9):842–7.

    Article  PubMed  Google Scholar 

  16. Hu Y, Converse C, Lyons MC, Hsu WH. Neural control of sweat secretion: a review. Br J Dermatol. 2018;178(6):1246–56.

    Article  CAS  PubMed  Google Scholar 

  17. Wade R, Llewellyn A, Jones-Diette J, Wright K, Rice S, Layton AM, et al. Interventional management of hyperhidrosis in secondary care: a systematic review. Br J Dermatol. 2018;179(3):599–608.

    Article  CAS  PubMed  Google Scholar 

  18. Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 Phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135–45.

    Article  PubMed  Google Scholar 

  19. Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128-38.e2.

    Article  CAS  PubMed  Google Scholar 

  20. Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(8):1149–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management strategies of palmar hyperhidrosis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:733–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lueangarun S, Sermsilp C, Tempark T. Topical botulinum toxin type A liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study. Dermatol Surg. 2018;44(8):1094–101.

    Article  CAS  PubMed  Google Scholar 

  23. Glaser DA, Coleman WP 3rd, Fan LK, Kaminer MS, Kilmer SL, Nossa R, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg. 2012;38(2):185–91.

    Article  CAS  PubMed  Google Scholar 

  24. Leclère FM, Moreno-Moraga J, Alcolea JM, Vogt PM, Royo J, Cornejo P, et al. Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow-up: a randomized blinded controlled trial. Lasers Surg Med. 2015;47(2):173–9.

    Article  PubMed  Google Scholar 

  25. Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol. 2012;11(1):59–63.

    PubMed  Google Scholar 

  26. Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, Nilforoushzadeh MA, Mirmohammadkhani M. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: a sham control study. Australas J Dermatol. 2015;56(4):279–84.

    Article  PubMed  Google Scholar 

  27. Swaile DF, Elstun LT, Benzing KW. Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists. Br J Dermatol. 2012;166(Suppl 1):22–6.

    Article  PubMed  Google Scholar 

  28. Thianboonsong T, Kanokrungsee S, Paichitrojjana A, Udompataikul M, Kamanamool N, Rojhirunsakool S. Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: a randomized controlled trial. Dermatol Ther. 2020;33(6): e14354.

    Article  CAS  PubMed  Google Scholar 

  29. Streker M, Reuther T, Verst S, Kerscher M. Axillary hyperhidrosis–efficacy and tolerability of an aluminium chloride antiperspirant. Prospective evaluation on 20 patients with idiopathic axillary hyperhidrosis. Hautarzt. 2010;61(2):139–44.

    Article  CAS  PubMed  Google Scholar 

  30. Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. J Drugs Dermatol. 2009;8(5):477–80.

    PubMed  Google Scholar 

  31. Streker M, Reuther T, Hagen L, Kerscher M. Hyperhidrosis plantaris—a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride. J Dtsch Dermatol Ges. 2012;10(2):115–9.

    PubMed  Google Scholar 

  32. Masur C, Soeberdt M, Kilic A, Knie U, Abels C. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2020;182(1):229–31.

    CAS  PubMed  Google Scholar 

  33. Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol. 2021;185(2):315–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hyun MY, Son IP, Lee Y, Choi HG, Park KY, Li K, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol. 2015;29(2):278–82.

    Article  CAS  PubMed  Google Scholar 

  35. Hebert AA, Glaser DA, Green L, Werschler WP, Forsha DW, Drew J, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatr Dermatol. 2019;36(1):89–99.

    Article  PubMed  Google Scholar 

  36. Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593–604.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hebert AA, Glaser DA, Green L, Hull C, Cather J, Drew J, et al. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analysis from a 44-week open-label extension study. Pediatr Dermatol. 2020;37(3):490–7.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Yokozeki H, Fujimoto T, Wanatabe S, Ogawa S, Fujii C. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: a randomized, double-blind, vehicle-controlled study. J Dermatol. 2022;49(1):86–94.

    Article  CAS  PubMed  Google Scholar 

  39. Kirsch B, Smith S, Cohen J, DuBois J, Green L, Baumann L, et al. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020;82(6):1321–7.

    Article  CAS  PubMed  Google Scholar 

  40. Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(3):279–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Artzi O, Loizides C, Zur E, Sprecher E. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97(9):1120–4.

    Article  CAS  PubMed  Google Scholar 

  42. Millán-Cayetano JF, Del Boz J, Toledo-Pastrana T, Nieto-Guindo M, García-Montero P, de Troya-Martín M. Initial study of transdermal oxybutynin for treating hyperhidrosis. J Dermatol. 2017;44(6):717–20.

    Article  PubMed  CAS  Google Scholar 

  43. Gollins CE, Carpenter A, Steen C, Bulinski H, Mahendran R. A retrospective analysis of the use of tap water iontophoresis for focal hyperhidrosis at a district general hospital: the patients’ perspective. J Dermatolog Treat. 2019;30(7):724–6.

    Article  CAS  PubMed  Google Scholar 

  44. Choi YH, Lee SJ, Kim DW, Lee WJ, Na GY. Open clinical trial for evaluation of efficacy and safety of a portable “dry-type” iontophoretic device in treatment of palmar hyperhidrosis. Dermatol Surg. 2013;39(4):578–83.

    Article  CAS  PubMed  Google Scholar 

  45. Dolianitis C, Scarff CE, Kelly J, Sinclair R. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australas J Dermatol. 2004;45(4):208–12.

    Article  PubMed  Google Scholar 

  46. Shimizu H, Tamada Y, Shimizu J, Ohshima Y, Matsumoto Y, Sugenoya J. Effectiveness of iontophoresis with alternating current (AC) in the treatment of patients with palmoplantar hyperhidrosis. J Dermatol. 2003;30(6):444–9.

    Article  PubMed  Google Scholar 

  47. Rajagopal R, Mallya NB. Comparative evaluation of botulinum toxin versus iontophoresis with topical aluminium chloride hexahydrate in treatment of palmar hyperhidrosis. Med J Armed Forces India. 2014;70(3):247–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Montaser-Kouhsari L, Zartab H, Fanian F, Noorian N, Sadr B, Nassiri-Kashani M, et al. Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. J Dermatolog Treat. 2014;25(4):337–41.

    Article  CAS  PubMed  Google Scholar 

  49. Wachal K, Bućko W, Staniszewski R, Majewska N, Błaszak M. Original paperEstimating the subjective efficiency after treatment of upper extremity hyperhidrosis using various methods. Adv Dermatol Allergol Postępy Dermatol Alergol. 2009;26(6):501–5.

    Google Scholar 

  50. Chia HY, Tan AS, Chong WS, Tey HL. Efficacy of iontophoresis with glycopyrronium bromide for treatment of primary palmar hyperhidrosis. J Eur Acad Dermatol Venereol. 2012;26(9):1167–70.

    Article  CAS  PubMed  Google Scholar 

  51. Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–23.

    CAS  PubMed  Google Scholar 

  52. Glaser DA, Pariser DM, Hebert AA, Landells I, Somogyi C, Weng E, et al. A prospective, nonrandomized, open-label study of the efficacy and safety of OnabotulinumtoxinA in adolescents with primary axillary hyperhidrosis. Pediatr Dermatol. 2015;32(5):609–17.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Flanagan KH, King R, Glaser DA. Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. J Drugs Dermatol. 2008;7(3):221–7.

    PubMed  Google Scholar 

  54. Basciani M, Di Rienzo F, Bizzarrini M, Zanchi M, Copetti M, Intiso D. Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study. Arch Dermatol Res. 2014;306(5):497–503.

    CAS  PubMed  Google Scholar 

  55. Cabreus P, Swartling C, Rystedt A. Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B. J Dermatol. 2019;46(10):874–8.

    Article  CAS  PubMed  Google Scholar 

  56. Kim WO, Kil HK, Yoon KB, Noh KU. Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg. 2009;35(5):833–8 (discussion 8).

    Article  CAS  PubMed  Google Scholar 

  57. Licht PB, Pilegaard HK. Severity of compensatory sweating after thoracoscopic sympathectomy. Ann Thorac Surg. 2004;78(2):427–31.

    Article  PubMed  Google Scholar 

  58. Adefusika JA, Brewer JD. OnabotulinumtoxinA therapy for compensatory hyperhidrosis. J Cosmet Dermatol. 2013;12(3):232–4.

    Article  PubMed  Google Scholar 

  59. Belin EE, Polo J. Treatment of compensatory hyperhidrosis with botulinum toxin type A. Cutis. 2003;71(1):68–70.

    PubMed  Google Scholar 

  60. Efthymiou CA, Thorpe JA. Compensatory hyperhidrosis: a consequence of truncal sympathectomy treated by video assisted application of botulinum toxin and reoperation. Eur J Cardiothorac Surg. 2008;33(6):1157–8.

    Article  PubMed  Google Scholar 

  61. Bechara FG, Sand M, Moussa G, Sand D, Altmeyer P, Hoffmann K, et al. Treatment of unilateral compensatory sweating after endoscopical thoracic sympathectomy for general hyperhidrosis with botulinum toxin A. Dermatol Surg. 2006;32(5):745–8.

    CAS  PubMed  Google Scholar 

  62. Hexsel D, Soirefmann M, Porto MD, Schilling-Souza J, Siega C. Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis. Dermatol Surg. 2015;41(Suppl 1):S93-100.

    Article  CAS  PubMed  Google Scholar 

  63. Junsuwan N, Manuskiatti W, Phothong W, Wanitphakdeedecha R. Fractional CO(2) laser-assisted Botulinum toxin type A delivery for the treatment of primary palmar hyperhidrosis. Lasers Med Sci. 2021;36(1):233–6.

    Article  PubMed  Google Scholar 

  64. Agamia NF, Sobhy N, Abd-Elraouf A, Tawfik A. Fractional CO2 laser for transcutaneous drug delivery of onabotulinum toxin in palmar hyperhidrosis. Dermatol Surg. 2021;47(5):678–83.

    Article  CAS  PubMed  Google Scholar 

  65. Issa MC, Torreão PS, Boechat M, Luiz R. Early investigations in drug delivery of onabotulinum toxin A using combined fractional ablative laser with impact ultrasound vs. injections of onabotulinum toxin A for palmar hyperhidrosis: a right-left comparison trial. Br J Dermatol. 2018;179(5):1168–9.

    Article  CAS  PubMed  Google Scholar 

  66. Wolosker N, de Campos JRM, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55(6):1696–700.

    Article  PubMed  Google Scholar 

  67. Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, Zagnoli A, Chassain-Le Lay M, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015;173(5):1163–8.

    Article  CAS  PubMed  Google Scholar 

  68. Wolosker N, Schvartsman C, Krutman M, Campbell TP, Kauffman P, de Campos JR, et al. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatr Dermatol. 2014;31(1):48–53.

    Article  PubMed  Google Scholar 

  69. Wolosker N, Teivelis MP, Krutman M, de Paula RP, de Campos JR, Kauffman P, et al. Long-term results of oxybutynin treatment for palmar hyperhidrosis. Clin Auton Res. 2014;24(6):297–303.

    Article  PubMed  Google Scholar 

  70. Wolosker N, Teivelis MP, Krutman M, de Paula RP, Kauffman P, de Campos JR, et al. Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis. Ann Vasc Surg. 2014;28(5):1106–12.

    Article  PubMed  Google Scholar 

  71. Müller C, Berensmeier A, Hamm H, Dirschka T, Reich K, Fischer T, et al. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2013;27(10):1278–84.

    PubMed  Google Scholar 

  72. Kaminaka C, Mikita N, Inaba Y, Kunimoto K, Okuhira H, Jinnin M, et al. Clinical and histological evaluation of a single high energy microwave treatment for primary axillary hyperhidrosis in Asians: a prospective, randomized, controlled, split-area comparative trial. Lasers Surg Med. 2019;51(7):592–9.

    Article  PubMed  Google Scholar 

  73. Rummaneethorn P, Chalermchai T. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis. Lasers Med Sci. 2020;35(5):1179–84.

    Article  PubMed  Google Scholar 

  74. Henning MAS, Ibler KS, Loft I, Ullum H, Erikstrup C, Nielsen KR, et al. Epidemiology of hyperhidrosis in danish blood donors. Acta Derm Venereol. 2021;101(4):adv00435.

    Article  PubMed  Google Scholar 

  75. Henning M, Ibler K, Loft I, Jennum P, Didriksen M, Ullum H, et al. Hyperhidrosis is associated with sleep disturbances, daytime tiredness, stress, and depression: a retrospective cohort study from the Danish Blood Donor Study. J Am Acad Dermatol.

  76. McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician. 2018;97(11):729–34.

    PubMed  Google Scholar 

  77. Solish MJ, Savinova I, Weinberg MJ. A practical approach to the diagnosis and treatment of palmar hyperhidrosis. Plast Reconstr Surg Glob Open. 2022;10(3): e4172.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Ooi K. The pitfalls of overtreatment: why more care is not necessarily beneficial. Asian Bioeth Rev. 2020;12(4):399–417.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The generous support of the LEO Foundation is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Department of Dermatology, Zealand University Hospital, Roskilde, Denmark

    Mattias A. S. Henning, Dorra Bouazzi & Gregor B. E. Jemec

  2. Department of Clinical Medicine, Faculty of Medical Health and Sciences, University of Copenhagen, Copenhagen, Denmark

    Mattias A. S. Henning, Dorra Bouazzi & Gregor B. E. Jemec

Authors
  1. Mattias A. S. Henning
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorra Bouazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregor B. E. Jemec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mattias A. S. Henning.

Ethics declarations

Funding

Mattias A.S. Henning was provided a grant for research from the LEO Foundation Denmark, grant number LF-18002.

Conflicts of interest

Mattias A.S. Henning was provided a grant for research from the LEO Foundation Denmark, grant number LF-18002. Dorra Bouazzi declares that she has no conflict of interest. Gregor B.E. Jemec reports grants and personal fees from AbbVie, personal fees from Coloplast, personal fees from Chemocentryx, personal fees from LEO pharma, grants from LEO Foundation, grants from Afyx, personal fees from Incyte, grants and personal fees from InflaRx, grants from Janssen-Cilag, grants and personal fees from Novartis, grants and personal fees from UCB, grants from CSL Behring, grants from Regeneron, grants from Sanofi, personal fees from Kymera, personal fees from VielaBio, outside the submitted work.

Availability of data and material

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Ethics approval

Ethics approval is not required as this is a literature review.

Consent

Informed consent was not obtained as this is a literature review of already published studies.

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Mattias A.S. Henning, Dorra Bouazzi and Gregor B.E. Jemec. The first draft of the manuscript was written by Mattias A.S. Henning and all authors commented on previous versions of the manuscript. All authors read and approved the final article.

Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henning, M.A.S., Bouazzi, D. & Jemec, G.B.E. Treatment of Hyperhidrosis: An Update. Am J Clin Dermatol 23, 635–646 (2022). https://doi.org/10.1007/s40257-022-00707-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-022-00707-x

Search

Navigation